LJ570

CAS No. 2252488-69-8

LJ570( —— )

Catalog No. M21635 CAS No. 2252488-69-8

LJ570 is the first PPARα/γ dual agonist (PPARαPPARγ with EC50s of 1.05 and 0.12 μM respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 338 Get Quote
5MG 519 Get Quote
10MG 743 Get Quote
25MG 1134 Get Quote
50MG 1512 Get Quote
100MG 2061 Get Quote
500MG 4131 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    LJ570
  • Note
    Research use only, not for human use.
  • Brief Description
    LJ570 is the first PPARα/γ dual agonist (PPARαPPARγ with EC50s of 1.05 and 0.12 μM respectively.
  • Description
    LJ570 is the first PPARα/γ dual agonist (PPARαPPARγ with EC50s of 1.05 and 0.12 μM respectively)
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2252488-69-8
  • Formula Weight
    394.5
  • Molecular Formula
    C27H22O3?
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Antonio L Luca P Carmen C et al. Identification of the First PPARα/γ Dual Agonist Able to Bind to Canonical and Alternate Sites of PPARγ and to Inhibit its Cdk5-Mediated Phosphorylation[J]. Journal of Medicinal Chemistry 2018:acs.jmedchem.8b00835-.
molnova catalog
related products
  • LB-100 (b)

    LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor. Phase 1.

  • IVA-337

    IVA-337 (Lanifibranor, IVA337)) is a potent, pan PPAR agonist with EC50 of 0.92 uM, 0.53 uM and 0.18 uM for human PPARα, PPARδ and PPARγ respectively.

  • BADGE

    Bisphenol a diglycidyl ether is a Standardized Chemical Allergen. The physiologic effect of bisphenol a diglycidyl ether is by means of Increased Histamine Release, and Cell-mediated Immunity.